Prevalence of H. pylori among asymptomatic HIV-positive and negative individuals in Central Ethiopia and efficacy of eradication therapy

Mesfun, Million Getachew; Gliga, Smaranda; Fuchs, André; Orth, Hans Martin; Schönfeld, Andreas; Luedde, Tom; Feldt, Torsten

doi:10.1016/j.ijregi.2022.01.007

Cited by 6 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the H. pylori eradication rate using standard triple therapy was 83.8% (244/291). This result was lower than the eradication rate reported from Northern Ethiopia, which was 90.3% [ 27 ] and higher than the study reported from Central Ethiopia, which was 50.0% [ 40 ]. Moreover, our findings are comparable with a recent systematic review on eradication rate of African studies, which was 79.0% [ 41 ].…”

Section: Discussioncontrasting

confidence: 71%

Prevalence of Helicobacter pylori infection and effectiveness of first-line triple eradication therapy among dyspeptic patients at hospitals in Hawassa City, Ethiopia: a cross-sectional follow-up study

Fekadu,

Kibru,

Tesfaye

et al. 2024

Gut Pathog

View full text Add to dashboard Cite

Background Dyspepsia is a common gastrointestinal illness sometimes associated with Helicobacter pylori (H. pylori) infection. Screening and eradicating the bacterium reduces the risk of infection-related complications. The aim of this study was to determine the magnitude of H. pylori infection among dyspeptic patients and the effectiveness of triple eradication therapy at hospitals in Hawassa city, Ethiopia. Results The prevalence of H. pylori infection was 48.5%. The H. pylori eradication rate using first-line triple therapy was 83.8%. Eradication therapy failure is associated with previous exposure compared to no exposure (AOR: 4.8, 95% CI: 1.37–10.97), a regimen for 10-days compared to 14-days (AOR: 4.05, 95% CI: 1.42–11.55), and self-reported side effects compared to no report (AOR: 2.5, 95% CI: 1.12–5.97). Based on Morisky-eight scale 230 (79.0%) patients were adherent to their triple therapy. Participants with no reports of adverse effects showed increased odds of adherence to triple therapy compared to those who had reports (AOR = 2.45, 95% CI: 1.29–4.62). Conclusions This study demonstrated that about half of adult dyspeptic patients were infected with H. pylori, and moderate eradication was observed. Factors such as previous history of eradication therapy, duration of the eradication regimen, and perception of potential adverse effects are associated with eradication rate and should be considered during the initiation of eradication therapy.

show abstract

Section: Discussioncontrasting

confidence: 71%

Prevalence of Helicobacter pylori infection and effectiveness of first-line triple eradication therapy among dyspeptic patients at hospitals in Hawassa City, Ethiopia: a cross-sectional follow-up study

Fekadu,

Kibru,

Tesfaye

et al. 2024

Gut Pathog

View full text Add to dashboard Cite

show abstract

“…In addition to the data in the tables, some local reports of data deserve citation. The prevalence of the H. pylori-HIV co-infection in single-center studies was 32.6% in Busan (Republic of Korea in the year 2019) using the serology method, 69.7% in Tehran (Iran in the year 2011) using the stool genotyping method, and 78.1% vs. 75.1% at Assela (Ethiopia in the year 2017) using the stool antigen method among asymptomatic individuals with and without HIV infection, respectively [23][24][25]. At Bologna in Italy, the prevalence was 55% and 58% by serology among asymptomatic past-intravenous drug users versus the general population, respectively, tested by serology, and 40% and 66% among symptomatic past-intravenous drug users versus the general population, respectively, tested by pathology [26].…”

Section: Resultsmentioning

confidence: 99%

Helicobacter pylori and Human Immunodeficiency Virus Co-Infection: Potential Implications for Future Gastric Cancer Risk

et al. 2023

View full text Add to dashboard Cite

Objective: Helicobacter pylori and human immunodeficiency virus (HIV) are both pandemic infections with variable geographic prevalence rates. H. pylori–HIV co-infection at the regional and sub-regional levels with a perspective on gastric cancer incidence is discussed. Design: Based on PRISMA guidelines, national data for H. pylori, HIV, and H. pylori–HIV co-infection were collected for the general population through December 2019. Joint temporal and geographical data for H. pylori and HIV infections in 48 countries were available and used to generate H. pylori–HIV co-infection estimates by cross-sectional analysis. These data were compared with gastric carcinoma statistics for the same countries. Results: The estimated global prevalence rate of H. pylori–HIV co-infection was 1.7 per 1000 people, representing 12.6 million people. Prevalence according to region was, in decreasing order, sub-Saharan Africa 21.9‰, Eastern Europe/Central Asia 4.3‰, Latin America/Caribbean 2.0 ‰, North America/Western/Southern/Northern Europe 1.1‰, Asia/Pacific 0.8‰, and North Africa/Middle East 0.1 ‰. The incidence and mortality rates for gastric carcinoma were higher in East/Pacific Asia, Southern/Andean Latin America, and Eastern Europe regions, and the incidence appeared to be 1.8-fold greater in H. pylori–HIV-infected people in East Asia. Conclusions: The population at risk of H. pylori–HIV co-infection is estimated to be 12.6 million people (2015 reference year). The heterogeneity of H. pylori–HIV co-infection across regions and sub-regions does not show a clear association with gastric carcinoma. Other methodological approaches with analytical studies (cohort, case–control) are required to measure the potential effect of H. pylori infection and its treatment on the incidence of gastric carcinoma in the large HIV–H. pylori-positive cohort.

show abstract

“…The literature has been acknowledging for a few years now that Helicobacter pylori is linked to several extra-gastric disorders. One of the most prevalent chronic infections globally is Helicobacter pylori , with prevalence rates ranging from 35 per cent in high-income nations (Zamani et al, 2018; Mesfun et al, 2022) to 79–90% in low-income nations (Asrat et al, 2004a,b; Hooi et al, 2017; Mesfun et al, 2022). Most of the time, the infection is asymptomatic, but it can also cause non-malignant problems including iron-deficiency anaemia, dyspeptic illness, and malignant complications like gastric and oesophagal cancer (Xie et al, 2013; Mesfun et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Detection and Prevalence of Syphilis, Hepatitis C Virus andHelicobacter pyloriCo-Infection among Pregnant Women attending Primary Health Centre, Mbodo-Aluu, Rivers State, Nigeria

Adim,

Nnamdi,

Ugboma

et al. 2024

Preprint

View full text Add to dashboard Cite

Due to the possible negative effects on both the mother and the foetus, co-infection with syphilis, hepatitis C virus (HCV), andHelicobacter pylori(H. pylori) in pregnant women is a serious public health problem. In this study, pregnant patients at the Mbodo Health Centre in Aluu, Port Harcourt, Rivers State, were asked to rate their prevalence of co-infection and related risk factors. 96 willing pregnant women gave consent for blood samples to be drawn, and ELISA and fast diagnostic kits were used to test the sera forHelicobacter pylori, hepatitis C, and syphilis. Results showed that 31.0% of the pregnant women hadHelicobacter pylori, but none had positive results for syphilis or the hepatitis C virus. The highest prevalence ofH. pyloriinfection, as determined by ELISA, was observed in the age group 30-39 years (37.5%), married groups (32.7%), secondary school education (44.0%), students (40.0%), and Christian religion (31.3%). This finding demonstrated thatH. pyloriwas more common in the study area than the other two pathogens. Pregnant women visiting the Primary Health Centre, Mbodo-Aluu, Rivers State had significant rates ofH. pyloriinfection with no coinfection with HCV and syphilis. This study emphasises the necessity of integrated screening and treatment initiatives during antenatal care. However, preventing unfavourable pregnancy outcomes and lowering the risk of vertical transmission to the baby need the early detection and treatment of these pathogens. Therefore, it is important to emphasise good knowledge and education about the infection in this area.

show abstract

Prevalence of H. pylori among asymptomatic HIV-positive and negative individuals in Central Ethiopia and efficacy of eradication therapy

Cited by 6 publications

References 28 publications

Prevalence of Helicobacter pylori infection and effectiveness of first-line triple eradication therapy among dyspeptic patients at hospitals in Hawassa City, Ethiopia: a cross-sectional follow-up study

Prevalence of Helicobacter pylori infection and effectiveness of first-line triple eradication therapy among dyspeptic patients at hospitals in Hawassa City, Ethiopia: a cross-sectional follow-up study

Helicobacter pylori and Human Immunodeficiency Virus Co-Infection: Potential Implications for Future Gastric Cancer Risk

Detection and Prevalence of Syphilis, Hepatitis C Virus andHelicobacter pyloriCo-Infection among Pregnant Women attending Primary Health Centre, Mbodo-Aluu, Rivers State, Nigeria

Contact Info

Product

Resources

About